XBIO NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Xenetic Biosciences Inc · Healthcare · Biotechnology

Open interactive chart View report data Download investor PDF
Latest close 2.64 USD
-5.1% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -4.1% below the Trend Line and sits at 6.2% of its 52-week range. The latest completed week returned -5.1%, after a -10.4% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 52/100. Near-term considerations: earnings are due in 13d.

Setup score 25 out of 100
Latest Close 2.64 USD 24 Jul 2026
1W Return -5.1% latest completed week
4W Return -10.4% short-term follow-through
12W Return -11.1% quarterly tape
Trend Breadth 32.7% 17 of 52 weeks active
Volume Ratio 1.7x vs 13-week average
What is working
  • Volume is elevated versus the 13-week average, confirming attention.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -5.1% Latest completed week; four-week move -10.4%. Indicator stack 18/4 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 52/100 45 relevant articles in the latest sentiment read. Event risk 13d Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -4.1% below the Trend Line and sits at 6.2% of its 52-week range. The latest completed week returned -5.1%, after a -10.4% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.7x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.3312-week average 0.42

12-week confirmation

Trend active10/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure8/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.33Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -10.4% over four weeks, -11.1% over 12 weeks, and -26.7% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-5.1%
4W-10.4%
12W-11.1%
26W-0.4%
52W-26.7%
Active trend streak0 weeks
Active weeks in one year17
Trend breadth32.7%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.55Latest activity-pressure read.
Pressure change-447.4%Four-week change in activity pressure.
Leadership-16.89Latest relative-leadership reading.
RS change-18.7%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 79% Model confidence 76%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength28/100Blend of value, momentum, and quality. Underlying universe rank 73; rank 1 is best.
Value40/100Relative valuation strength. Underlying universe rank 61; rank 1 is best.
Quality39/100Profitability and accounting quality. Underlying universe rank 62; rank 1 is best.
Momentum41/100Medium-term price momentum. Underlying universe rank 60; rank 1 is best.
Growth41/100Revenue and earnings growth. Underlying universe rank 60; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
1.9x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-30.1%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
100.0%
Gross profit retained from each unit of revenue.
Operating margin
-74.0%
Operating profit retained from revenue.
Free-cash-flow margin
-57.1%
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
23.5%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-66.2%
Net share repurchases relative to market value.
Shareholder yield
-66.2%
Dividend yield plus net buyback yield.
Net debt / EBITDA
3.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity1 / 0

1 acquisitions and 0 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment52/100

Weighted news tone is neutral across 45 relevant articles.

9 positive · 30 neutral · 6 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings13dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-81.0%Distance below the 52-week high.
13-week volatility4.7%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2613 weeks finished lower.
Best week+22.6%Week of 13 Mar.
Worst week-16.6%Week of 27 Mar.
Latest week-5.1%Week of 24 Jul.

Shape of recent returns

Strong gains7
Modest gains6
Flat weeks0
Modest losses5
Sharp losses8
Recent vol4.7%13-week weekly-return volatility.
Base vol16.8%52-week weekly-return volatility.
Up/down split25/27Count of positive and negative weeks in the 52-week window.
Average skew10.9% / -9.1%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape25/100

Trend, activity pressure, participation, and risk combine to a 25/100 tape read.

 Indicator analysis49/100

Latest 12-week confirmation: trend 10/12, activity pressure 8/12, relative leadership 0/12.

Activity pressure 0.33; No reversal markers Factors35/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 98 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment52/100

Weighted news tone is neutral across 45 relevant articles.

Xenetic Biosciences, Inc. Revenue Breakdown – MUN:3XB0 Insiders1 / 0

1 acquisitions and 0 disposals in the latest 180-day insider tape.

 Earnings13d

Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 20262.64 USD-5.1%2.75 USD3.50 USD-0.55-16.89133.5KOff
17 Jul 20262.78 USD1.7%2.74 USD3.50 USD-0.49-14.7180.8KOn
10 Jul 20262.73 USD-1.3%2.71 USD3.51 USD-0.41-20.4790.2KOn
3 Jul 20262.77 USD-5.9%2.70 USD3.52 USD-0.13-19.1277.5KOn
26 Jun 20262.94 USD5.2%2.70 USD3.52 USD0.16-14.2270.9KOn
19 Jun 20262.80 USD-12.5%2.69 USD3.53 USD0.39-22.8293.5KOn
12 Jun 20263.20 USD3.6%2.67 USD3.53 USD0.57-9.9774.0KOn
5 Jun 20263.09 USD-1.9%2.65 USD3.53 USD0.59-11.51156.7KOn
29 May 20263.15 USD4.0%2.64 USD3.53 USD0.63-14.2632.4KOn
22 May 20263.03 USD-0.5%2.64 USD3.53 USD0.60-15.6643.6KOn
15 May 20263.04 USD-0.8%2.68 USD3.53 USD0.64-14.8045.0KOn
8 May 20263.07 USD3.4%2.71 USD3.53 USD0.75-14.77114.3KOff
1 May 20262.97 USD-2.6%2.82 USD3.53 USD0.76-13.6626.8KOff
24 Apr 20263.05 USD-13.6%2.83 USD3.54 USD0.86-10.4071.0KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.